Novavax (NVAX) Price & Analysis

Compare

10,061 Followers

NVAX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.01 - $15.22

Previous CloseN/A

Volume4.15M

Average Volume (3M)6.17M

Market Cap

$1.39B

Enterprise Value$721.89M

Total Cash (Recent Filing)$623.05M

Total Debt (Recent Filing)$228.49M

Price to Earnings (P/E)3.8

Beta1.60

Next Earnings

Nov 05, 2025

EPS Estimate

-0.49

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.62

Shares Outstanding162,421,650

10 Day Avg. Volume4,288,500

30 Day Avg. Volume6,171,254

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.52

Enterprise Value/Revenue0.67

Enterprise Value/Gross Profit0.76

Enterprise Value/Ebitda1.46

Forecast

1Y Price Target

$11.00

Price Target Upside28.65% Upside

Rating ConsensusHold

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Cost ManagementNovavax has been successful in trimming operating expenses by about two-thirds from COVID highs and cleaning up its balance sheet.

Vaccine PlatformAt the core of the positive view of Novavax is the company’s proprietary vaccine platform based on a recombinant protein nanoparticle and Matrix-M adjuvant.

Bears Say

Commercialization ChallengesSanofi's commercialization of the Nuvaxovid COVID-19 vaccine may face hurdles to meaningful revenue growth near-term with a restricted US label and continued rocky COVID sentiment.

Market ShareNovavax has reduced peak market share estimates for Nuvaxovid from 18% to 14% due to uncertainty in the COVID market.

Novavax News

CDC panel votes against requiring prescriptions for Covid shots, Bloomberg says

15:27 EDT CDC panel votes against requiring prescriptions for Covid shots, Bloomberg says Published first on TheFly –...

10d ago

PFE

BNTX

CDC panel votes to end universal Covid vaccine recommendation, Bloomberg says

The Centers for Disease Control and Prevention’s new panel of vaccine advisers voted Friday to end the agency’s...

10d ago

GSK

PFE

Trump Trade: Trump expected to extend deadline for TikTok sale

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

15d ago

NSC

PFE

Covid vaccine makers drop as WaPo says officials to link shots to child deaths

Shares of Pfizer (PFE), Moderna (MRNA), and BioNTech (BNTX) are lower around midday after the Washington Post reported...

18d ago

PFE

BNTX

Trump officials to link COVID shots to child deaths, WaPo reports

Health officials in the Trump Administration plan to link coronavirus vaccines to the deaths of 25 children as...

18d ago

AZN

PFE

Trump Trade: U.S. President asks SCOTUS to uphold tariffs

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

26d ago

CAT

Novavax’s COVID-19 vaccine Nuvaxovid approved in Japan

Novavax (NVAX) announced a milestone payment from Takeda (TAK) has been triggered by regulatory approval for Novavax’s COVID-19...

26d ago

TAK

NVAX

FDA vaccine chief overruled scientists on Covid shot access, NY Times reports

The FDA’s vaccine chief overruled staff scientists who favor widespread access to Covid shots, according to memos released...

26d ago

PFE

BNTX

Novavax ‘applauds’ President Trump’s call for available COVID-19 vaccine data

Novavax (NVAX) issued the following statement on publicly available COVID-19 vaccine data: “Novavax is a U.S.-based biotechnology company...

26d ago

NVAX

Florida surgeon general says state will eliminate vaccine mandates

Joseph Ladapo, the State Surgeon General of Florida, said that the state will work to eliminate all vaccine...

26d ago

GSK

PFE

Challenging Market Dynamics and Regulatory Hurdles Lead to Sell Rating for Novavax

Analyst Alec Stranahan from Bank of America Securities maintained a Sell rating on Novavax and keeping the price...

8d ago

NVAX

Optimistic Outlook on Novavax: Strategic Positioning and Vaccine Developments Drive Buy Rating

Analyst Thomas Shrader of BTIG maintained a Buy rating on Novavax, retaining the price target of $19.00. Thomas...

28d ago

NVAX

Kohl’s, Bill.com, Novavax, Jazz, Nvidia: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($KSS) ), ( ($BILL) ), ( ($NVAX) ), ( ($JAZZ)...

1M ago

KSS

BILL

Novavax Gains FDA Approval for Nuvaxovid Vaccine

Novavax ( ($NVAX) ) has issued an announcement. On August 27, 2025, Novavax announced that the FDA approved...

1M ago

NVAX

NVAX FAQ

What was Novavax’s price range in the past 12 months?

Novavax lowest stock price was $5.01 and its highest was $15.22 in the past 12 months.

What is Novavax’s market cap?

Novavax’s market cap is $1.39B.

When is Novavax’s upcoming earnings report date?

Novavax’s upcoming earnings report date is Nov 05, 2025 which is in 36 days.

How were Novavax’s earnings last quarter?

Novavax released its earnings results on Aug 06, 2025. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.008 by $0.612.

Is Novavax overvalued?

According to Wall Street analysts Novavax’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novavax pay dividends?

Novavax does not currently pay dividends.

What is Novavax’s EPS estimate?

Novavax’s EPS estimate is -0.49.

How many shares outstanding does Novavax have?

Novavax has 162,421,650 shares outstanding.

What happened to Novavax’s price movement after its last earnings report?

Novavax reported an EPS of $0.62 in its last earnings report, beating expectations of $0.008. Following the earnings report the stock price went up 12.63%.

Which hedge fund is a major shareholder of Novavax?

Currently, no hedge funds are holding shares in NVAX

Novavax Stock Smart Score

Neutral

Fundamentals

Return on Equity

30.06%

Trailing 12-Months

Asset Growth

-26.51%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Novavax

Novavax, Inc. is a biotechnology company focused on the development and commercialization of innovative vaccines to prevent serious infectious diseases. The company primarily operates in the biopharmaceutical sector, with a strong emphasis on vaccine development using its proprietary nanoparticle technology platform. Novavax's core products include vaccines for respiratory syncytial virus (RSV), seasonal influenza, and COVID-19, as well as other infectious diseases.

Novavax (NVAX) Earnings & Revenues

Historic Earnings Reports

NVAX Company Deck

NVAX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted several positive achievements, including a significant milestone payment from the BLA approval in the U.S., successful cost reduction strategies, and promising data from the CIC and flu programs. However, these were somewhat offset by a notable decrease in total revenue compared to the previous year and the financial implications of a required post-marketing commitment study. Overall, the sentiment leans towards positive due to the outweighed highlights.View all NVAX earnings summaries

NVAX Stock 12 Month Forecast

Average Price Target

$11.00

▲(28.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","20":"$20","8.75":"$8.75","12.5":"$12.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,8.75,12.5,16.25,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.55,8.430769230769231,9.311538461538461,10.192307692307692,11.073076923076922,11.953846153846154,12.834615384615384,13.715384615384615,14.596153846153847,15.476923076923075,16.357692307692307,17.23846153846154,18.119230769230768,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.55,7.815384615384615,8.080769230769231,8.346153846153847,8.611538461538462,8.876923076923077,9.142307692307693,9.407692307692308,9.673076923076923,9.938461538461539,10.203846153846154,10.46923076923077,10.734615384615385,{"y":11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.55,7.507692307692308,7.4653846153846155,7.423076923076923,7.38076923076923,7.338461538461538,7.296153846153846,7.253846153846154,7.211538461538462,7.1692307692307695,7.1269230769230765,7.084615384615384,7.042307692307692,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.38,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.32,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.04,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.69,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.33,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.41,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.56,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.55,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >